<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lahdeniemi IAK</submitter><funding>Terveyden Tutkimuksen Toimikunta</funding><funding>Institute for Molecular Medicine Finland: Helsingin yliopisto Suomen molekyylilaaketieteen instituutti</funding><funding>Core</funding><pagination>bio059623</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9770245</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(12)</volume><pubmed_abstract>Preclinical tumor models with native tissue microenvironments provide essential tools to understand how heterogeneous tumor phenotypes relate to drug response. Here we present syngeneic graft models of aggressive, metastasis-prone histopathology-specific NSCLC tumor types driven by KRAS mutation and loss of LKB1 (KL): adenosquamous carcinoma (ASC) and adenocarcinoma (AC). We show that subcutaneous injection of primary KL; ASC cells results in squamous cell carcinoma (SCC) tumors with high levels of stromal infiltrates, lacking the source heterogeneous histotype. Despite forming subcutaneous tumors, intravenously injected KL;AC cells were unable to form lung tumors. In contrast, intravenous injection of KL;ASC cells leads to their lung re-colonization and lesions recapitulating the mixed AC and SCC histopathology, tumor immune suppressive microenvironment and oncogenic signaling profile of source tumors, demonstrating histopathology-selective phenotypic dominance over genetic drivers. Pan-ERBB inhibition increased survival, while selective ERBB1/EGFR inhibition did not, suggesting a role of the ERBB network crosstalk in resistance to ERBB1/EGFR. This immunocompetent NSCLC lung colonization model hence phenocopies key properties of the metastasis-prone ASC histopathology, and serves as a preclinical model to dissect therapy responses and metastasis-associated processes.</pubmed_abstract><journal>Biology open</journal><pubmed_title>Development of an adenosquamous carcinoma histopathology - selective lung metastasis model.</pubmed_title><pmcid>PMC9770245</pmcid><funding_grant_id>307111</funding_grant_id><pubmed_authors>Nagaraj AS</pubmed_authors><pubmed_authors>Lahdeniemi IAK</pubmed_authors><pubmed_authors>Verschuren EW</pubmed_authors><pubmed_authors>Devlin JR</pubmed_authors><pubmed_authors>Talwelkar SS</pubmed_authors><pubmed_authors>Bao J</pubmed_authors><pubmed_authors>Hemmes A</pubmed_authors><pubmed_authors>Seref Vujaklija C</pubmed_authors><pubmed_authors>Kiss EA</pubmed_authors><pubmed_authors>Linnavirta N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development of an adenosquamous carcinoma histopathology - selective lung metastasis model.</name><description>Preclinical tumor models with native tissue microenvironments provide essential tools to understand how heterogeneous tumor phenotypes relate to drug response. Here we present syngeneic graft models of aggressive, metastasis-prone histopathology-specific NSCLC tumor types driven by KRAS mutation and loss of LKB1 (KL): adenosquamous carcinoma (ASC) and adenocarcinoma (AC). We show that subcutaneous injection of primary KL; ASC cells results in squamous cell carcinoma (SCC) tumors with high levels of stromal infiltrates, lacking the source heterogeneous histotype. Despite forming subcutaneous tumors, intravenously injected KL;AC cells were unable to form lung tumors. In contrast, intravenous injection of KL;ASC cells leads to their lung re-colonization and lesions recapitulating the mixed AC and SCC histopathology, tumor immune suppressive microenvironment and oncogenic signaling profile of source tumors, demonstrating histopathology-selective phenotypic dominance over genetic drivers. Pan-ERBB inhibition increased survival, while selective ERBB1/EGFR inhibition did not, suggesting a role of the ERBB network crosstalk in resistance to ERBB1/EGFR. This immunocompetent NSCLC lung colonization model hence phenocopies key properties of the metastasis-prone ASC histopathology, and serves as a preclinical model to dissect therapy responses and metastasis-associated processes.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2024-11-19T17:54:08.93Z</modification><creation>2024-11-19T17:54:08.93Z</creation></dates><accession>S-EPMC9770245</accession><cross_references><pubmed>36355420</pubmed><doi>10.1242/bio.059623</doi></cross_references></HashMap>